Algert Global LLC Invests $704,000 in Bioventus Inc. (NYSE:BVS)

Algert Global LLC purchased a new position in Bioventus Inc. (NYSE:BVS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 67,020 shares of the company’s stock, valued at approximately $704,000.

A number of other large investors also recently modified their holdings of BVS. Vanguard Group Inc. lifted its position in shares of Bioventus by 18.7% in the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after buying an additional 388,174 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Bioventus by 38.7% in the 4th quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock worth $9,289,000 after buying an additional 246,645 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after buying an additional 176,442 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Bioventus by 55.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 427,422 shares of the company’s stock worth $4,488,000 after buying an additional 152,311 shares during the last quarter. Finally, Sheets Smith Investment Management bought a new position in shares of Bioventus in the 4th quarter worth about $1,499,000. 62.94% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BVS has been the topic of several recent research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the company a “buy” rating in a research report on Wednesday.

Bioventus Trading Down 1.5%

Shares of NYSE:BVS opened at $6.70 on Monday. The company has a market cap of $549.02 million, a PE ratio of -10.98 and a beta of 0.95. The company’s 50-day moving average price is $8.40 and its 200 day moving average price is $10.05. Bioventus Inc. has a fifty-two week low of $5.27 and a fifty-two week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Insiders Place Their Bets

In other Bioventus news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. The trade was a 3.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Leonard Singleton sold 6,498 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the sale, the chief financial officer now owns 118,817 shares in the company, valued at $1,210,745.23. This trade represents a 5.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,208 shares of company stock worth $226,138. 32.90% of the stock is owned by corporate insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.